KZIA (Kazia Therapeutics) צמיחת רווח נקי למניה השנה

Current annual EPS growth reflects the dynamics of Kazia Therapeutics (KZIA), the developer of paxalisib, which is capable of crossing the blood-brain barrier for glioblastoma therapy, with the indicator recorded at 23.00. Business prospects rely on clinical test results and funding, while the stability of the R&D team is ensured by the recruitment of specialized experts and trial managers.
פילוחי מדדים פיננסיים ומדדי שוק עבור Kazia Therapeutics Ltd (KZIA)

This metric is calculated as the year-over-year percentage change in net earnings per share, reflecting the business scaling rate. An increase in this value signals accelerating profitability, while a decrease indicates stagnation or losses. For Kazia Therapeutics (KZIA), the annual EPS trend depends directly on the clinical success of paxalisib in treating brain tumors and its ability to cross the blood-brain barrier.